Abstract：
Non-alcoholic fatty liver disease (NAFLD) is a common concomitant disease in adults with type 2 diabetes mellitus (T2DM) and prediabetes. Therefore, T2DM/NAFLD patient populations are at high risk for cardiovascular disease. The occurrence and progression of non-alcoholic fatty liver disease-related liver fibrosis and cardiovascular disease have a severe impact on the patient\'s prognosis and mortality rate. The American Diabetes Association\'s 2024 \"Guidelines for the Standardized Management of Diabetes\" put forward recommendations relevant to the screening, evaluation, treatment, and management of NAFLD in T2DM and prediabetic populations, as well as liver fibrosis. The important measures for decelerating liver inflammation and fibrosis progression and the risk of cardiovascular disease are based on improvements in lifestyle methods, weight loss, and blood sugar control.
非酒精性脂肪性肝病（NAFLD）为成人2型糖尿病（T2DM）及糖尿病前期常见伴发疾病，T2DM/NAFLD患者为心血管疾病的高危人群，NAFLD及其相关肝纤维化的发生和发展、心血管疾病及其相关死亡严重影响患者预后。2024年美国糖尿病学会《糖尿病标准化管理指南》针对T2DM及糖尿病前期人群NAFLD，以及肝纤维化的筛查、评估、治疗及管理提出相关建议。在改善生活方式基础上，减重、控制血糖是减缓肝脏炎症及肝纤维化进展、降低心血管疾病风险的重要措施。.
非酒精性脂肪性肝病（NAFLD）为成人2型糖尿病（T2DM）及糖尿病前期常见伴发疾病，T2DM/NAFLD患者为心血管疾病的高危人群，NAFLD及其相关肝纤维化的发生和发展、心血管疾病及其相关死亡严重影响患者预后。2024年美国糖尿病学会《糖尿病标准化管理指南》针对T2DM及糖尿病前期人群NAFLD，以及肝纤维化的筛查、评估、治疗及管理提出相关建议。在改善生活方式基础上，减重、控制血糖是减缓肝脏炎症及肝纤维化进展、降低心血管疾病风险的重要措施。.
摘要：
暂无翻译
